Haidar, Ahmad, Elleri, Daniela, Kumareswaran, Kavita, Leelarathna, Lalantha, Allen, Janet M, Caldwell, Karen, Murphy, Helen R, Wilinska, Malgorzata E, Acerini, Carlo L, Evans, Mark L, Dunger, David B, Nodale, Marianna and Hovorka, Roman (2013) Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes:reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care, 36 (10). e173-174. ISSN 0149-5992
Preview |
PDF (Manuscript)
- Published Version
Download (57kB) | Preview |
Abstract
Insulin aspart, lispro, or glulisine are recommended in pump-treated type 1 diabetes (T1D). Aspart pharmacokinetics has been studied (1), but little is known about its reproducibility and associations with anthropometric and clinical factors. We analyzed retrospectively data collected in 70 pump-treated subjects with T1D, comprising 39 females, 46 young, with mean (SD) BMI 22.7 (4.2) kg/m2, A1C 8.1% (1.3) (65.3 [14.4] mmol/mol), and total daily insulin 0.8 (0.3) units/kg/day, who were undergoing investigations, with ethical approval, of closed-loop insulin delivery. Participants/guardians signed consent/assent as appropriate. Participants were admitted twice to the research facility, 1–6 weeks apart, for 15–37 h, and consumed 1–4 meals accompanied by prandial insulin aspart. Basal aspart was delivered using closed-loop insulin delivery or conventional pump therapy. Venous blood samples were collected every 30–60 min to measure plasma insulin (Invitron, Monmouth, U.K.). From 5,804 plasma insulin measurements, we estimated, using a two-compartment model, the time-to-peak plasma insulin concentration (tmax [min]), the metabolic clearance rate of insulin (MCR in mL/kg/min), and the background residual plasma insulin concentration (mU/L). Results are presented in Table 1. Sex differences in aspart kinetics were not observed. Aspart pharmacokinetics was weakly influenced by common clinical and anthropometric factors, because less than 20% of intersubject variability was explained by sex, BMI, total daily dose, A1C, and diabetes duration.
Item Type: | Article |
---|---|
Additional Information: | © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
Uncontrolled Keywords: | age factors,body weight,diabetes mellitus, type 1,female,humans,insulin aspart,male,retrospective studies,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School Faculty of Science > School of Environmental Sciences |
UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
Depositing User: | Pure Connector |
Date Deposited: | 25 May 2016 15:00 |
Last Modified: | 19 Oct 2023 01:42 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/59057 |
DOI: | 10.2337/dc13-0485 |
Downloads
Downloads per month over past year
Actions (login required)
View Item |